One additional trial worth mentioning is the EORTC sponsored trastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (TREAT CTC, NCT01548677). Here, ERBB2 is linked to breast carcinoma.